Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Single Institution Study of Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab

NCT01331616 is registered in ClinicalTrials.gov with West Penn Allegheny Health System as lead sponsor.

NCT NCT01331616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01331616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Single Institution Study of Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab
Lead sponsor
West Penn Allegheny Health System
Phase
Phase 1
Overall status
Withdrawn
Start date
March 31, 2011
Completion date
July 31, 2012
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, optic neuropathy